Active Ingredient: dulaglutide
Dosage Forms & Strengths:
Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen
Mechanism of Action: GLP-1 receptor agonist
First Approval: US (Sep 18, 2014), EU (Nov 25, 2014)
Revenue Analysis1
Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…
Shots:
Matt spoke about the new research program for multiple genetic segments of arrhythmogenic cardiomyopathy
He also highlighted Renovacor’s research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI)
The interview shows Renovacor’s pipeline expansion to develop transformative therapies in genetically-driven cardiovascular diseases
Smriti: Please give readers a brief insight…
Shots:
Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022
He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseases
The interview summarizes…

